Our results show that two interleukins, IL-13 and IL-33, closely related to one another, are increased in a specific subset of systemic sclerosis patients with interstitial lung disease, a relevant complication conferring a high risk for mortality and morbidity. Here, IL33 is linked to systemic sclerosis.